Atara Biotherapeutics has submitted a Biologics License Application (BLA) for Tabelecleucel (Tab-cel), a for treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) with the US Food and Drug Administration (FDA). There are currently no FDA approved therapies in this treatment setting. It is indicated as… Read More
Studies of interactions between two lab-generated monoclonal antibodies (mAbs) and an essential Epstein-Barr virus (EBV) protein have uncovered targets that could be exploited in designing treatments and vaccines for the virus. The research was led by Jeffrey Cohen and colleagues from the National Institute of Allergy… Read More
Pierre Fabre will commercialise and distribute the first approved allogeneic T cell immunotherapy in Europe following the transfer of the European Commission marketing authorisation of Ebvallo (tabelecleucel) from Atara Biotherapeutics. Ebvallo is the only approved therapy for the treatment of relapsed or refractory Epstein‑Barr virus positive post‑transplant… Read More
The latest episode of the DDW Highlights podcast is now available for download. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Over the last seven days we’ve seen discoveries that could… Read More
News round-up for 24-28 October by DDW Digital Content Editor Diana Spencer Over the last seven days we’ve seen discoveries that could lead to new treatments for Covid-19, pancreatic cancer and Epstein-Barr virus, as well as the launch of the UK’s largest health research programme and the innovative application of… Read More
A panel of investigational monoclonal antibodies (mAbs) targeting different sites of the Epstein-Barr virus (EBV) have been shown to block infection when tested in human cells in a laboratory setting. One of the experimental mAbs provided nearly complete protection against EBV infection and lymphoma when tested in… Read More
The National Institute of Allergy and Infectious Diseases (NIAID) has launched a clinical trial to evaluate an investigational preventative vaccine for Epstein-Barr virus (EBV). Part of the National Institutes of Health, NIAID will conduct a Phase 1 study at the NIH Clinical Center in Bethesda, Maryland to evaluate the… Read More
